Private and public sectors have collaborated to launch a biopharmaceutical company to produce protein drugs, with the intention of helping local companies manufacture such drugs for clinical trials.
INVESTORS
Active pharmaceutical ingredient maker Formosa Laboratories Inc (台耀化學), the government-funded Development Center for Biotechnology (DCB) and the state-run National Development Fund are all investors in EirGenix Inc (台康生技), capitalized at NT$540 million (US$18.17 million).
DCB and Formosa Laboratories each have an 18 percent holding in the new company launched yesterday, while the National Development Fund has a 12 percent stake.
EirGenix has the capacity to produce 800 liters of protein drugs and is set to expand its capacity to 1,500 liters in the second quarter of next year, and to 30,000 liters within eight to 10 years, EirGenix chief executive officer Liu Lee-cheng (劉理成) said.
BREAST CANCER
The company is also developing a generic drug for treating breast cancer, and the company estimated the worldwide market for such a drug to be US$6 billion, according to Liu.
EirGenix is set to break even in 2016 and become a listed company in Taiwan in 2017, Liu said.
The demise of the coal industry left the US’ Appalachian region in tatters, with lost jobs, spoiled water and countless kilometers of abandoned underground mines. Now entrepreneurs are eyeing the rural region with ambitious visions to rebuild its economy by converting old mines into solar power systems and data centers that could help fuel the increasing power demands of the artificial intelligence (AI) boom. One such project is underway by a non-profit team calling itself Energy DELTA (Discovery, Education, Learning and Technology Accelerator) Lab, which is looking to develop energy sources on about 26,305 hectares of old coal land in
Taiwan’s exports soared 56 percent year-on-year to an all-time high of US$64.05 billion last month, propelled by surging global demand for artificial intelligence (AI), high-performance computing and cloud service infrastructure, the Ministry of Finance said yesterday. Department of Statistics Director-General Beatrice Tsai (蔡美娜) called the figure an unexpected upside surprise, citing a wave of technology orders from overseas customers alongside the usual year-end shopping season for technology products. Growth is likely to remain strong this month, she said, projecting a 40 percent to 45 percent expansion on an annual basis. The outperformance could prompt the Directorate-General of Budget, Accounting and
Netflix on Friday faced fierce criticism over its blockbuster deal to acquire Warner Bros Discovery. The streaming giant is already viewed as a pariah in some Hollywood circles, largely due to its reluctance to release content in theaters and its disruption of traditional industry practices. As Netflix emerged as the likely winning bidder for Warner Bros — the studio behind Casablanca, the Harry Potter movies and Friends — Hollywood’s elite launched an aggressive campaign against the acquisition. Titanic director James Cameron called the buyout a “disaster,” while a group of prominent producers are lobbying US Congress to oppose the deal,
Two Chinese chipmakers are attracting strong retail investor demand, buoyed by industry peer Moore Threads Technology Co’s (摩爾線程) stellar debut. The retail portion of MetaX Integrated Circuits (Shanghai) Co’s (上海沐曦) upcoming initial public offering (IPO) was 2,986 times oversubscribed on Friday, according to a filing. Meanwhile, Beijing Onmicro Electronics Co (北京昂瑞微), which makes radio frequency chips, was 2,899 times oversubscribed on Friday, its filing showed. The bids coincided with Moore Threads’ trading debut, which surged 425 percent on Friday after raising 8 billion yuan (US$1.13 billion) on bets that the company could emerge as a viable local competitor to Nvidia
RSS